CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Hainan Poly Pharm Co Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Hainan Poly Pharm Co Ltd
Guilinyang Economic Development Zone
Meilan District
Phone: +86 89866661090p:+86 89866661090 HAIKOU, HAN  571127  China Ticker: 300630300630
Business Summary
Hainan Poly Pharm Co Ltd is a company engaged in research and development, production and sales of drugs. The Company operates five segments. The Anti-Allergic segment is engaged in the production of desloratadine dispersible tablets, desloratadine dry suspension and desloratadine tablets. The Antibiotic segment provides levofloxacin hydrochloride capsules and azithromycin dry suspension for the treatment of bacterial infections. The Nonsteroidal Anti-inflammatory Drugs segment provides diclofenac sodium enteric-coated sustained-release capsule products for the treatment of arthritis and dysmenorrhea. The Digestive segment is involved in providing trimebutine maleate tablets to treat abdominal pain, diarrhea, and irritable bowel syndrome. The Company also operates Other segment.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/202412/31/2023Yes----

Industries
SIC Code Description
2834 Pharmaceutical preparations
7389 Business services, not elsewhere classified
8711 Engineering services
8999 Services, not elsewhere classified

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board, General Manager MinhuaFan 62 10/30/2012 10/30/2012
Chief Financial Officer, Deputy General Manager, Director TongningLuo 47 11/27/2018 10/30/2012
Deputy General Manager, Secretary of the Board, Director MaoZhou 53 6/1/2015 1/1/2009
6 additional Officers and Directors records available in full report.

General Information
Number of Employees: 1,565 (As of 12/31/2023)
Outstanding Shares: 448,542,393 (As of 9/30/2024)
Shareholders: 40,004
Stock Exchange: SHE
Fax Number: +86 89865710369


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, November 20, 2024